Open Access<p>Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration</p>
Author(s) -
Justus G. Garweg
Publication year - 2019
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s185756
Subject(s) - medicine , macular degeneration , aflibercept , ophthalmology , dosing , neovascular glaucoma , bevacizumab , pharmacology , endocrinology , diabetic retinopathy , chemotherapy , diabetes mellitus
To review published evidence for a treatment interval extension to ≥12-weeks in neovascular macular degeneration treated with intravitreal Aflibercept.